Ikena Oncology Inc (NASDAQ: IKNA) Is A Good Bet For Risk-Tolerant Investors

Ikena Oncology Inc (NASDAQ:IKNA)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 0.36. At the close of trading, the stock’s price was $1.33, to imply an increase of 5.56% or $0.07 in intraday trading. The IKNA share’s 52-week high remains $7.64, putting it -474.44% down since that peak but still an impressive 23.31% since price per share fell to its 52-week low of $1.02. The company has a valuation of $64.19M, with an average of 428.38K shares over the past 3 months.

Ikena Oncology Inc (NASDAQ:IKNA) trade information

After registering a 5.56% upside in the last session, Ikena Oncology Inc (IKNA) has traded red over the past five days. The stock hit a weekly high of 1.3799, jumping 5.56% in its intraday price action. The 5-day price performance for the stock is 0.00%, and -14.47% over 30 days. With these gigs, the year-to-date price performance is -32.49%.

Ikena Oncology Inc (IKNA) estimates and forecasts

Looking at statistics comparing Ikena Oncology Inc share performance against respective industry, we note that the company has underperformed competitors. Ikena Oncology Inc (IKNA) shares are -64.91% down over the last 6 months, with its year-to-date growth rate lower than industry average at 7.98% against 13.30%. Revenue is forecast to shrink -5.10% this quarter before jumping 11.40% for the next one. The rating firms project that company’s revenue will shrink -23.60% compared to the previous financial year.

Revenue forecast for the current quarter as set by 4 analysts is $1.75 million. Meanwhile, for the quarter ending Jun 2024, a total of 4 analyst(s) estimate revenue growth to $1.75 million.Earnings reports from the last fiscal year show that sales brought in $5.31 million and $3.08 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -67.10% before dropping -43.20% in the following quarter.

IKNA Dividends

Ikena Oncology Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Ikena Oncology Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.